Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formoterol for BAT Activation
NCT05553184Completed
- Sponsor
- Université de Sherbrooke
- Start
- Jul 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of formoterol in obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Université de Sherbrooke. Primary endpoint: Change in Brown Adipose Tissue thermogenesis. Started Jul 2022; status: completed.
02
Drugs
formoterol
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05553184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05553184.